Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement

Amsterdam, June 06, 2017 – A new position statement by the European Menopause and Andropause Society(EMAS) published in the journal Maturitas summarises the evidence about drug holidays from bisphosphonates and denosumab in women with postmenopausal osteoporosis. Osteoporosis affects 1 in 3 women. Bisphosphonates, such as alendronate, risendronate and zoledronic acid, and denosumab are used extensively…

Details